CSF2 and cancer: Our pharmacovigilance analysis also detected significant risk of sepsis in cancer patients who received ADCs and colony-stimulating factors (G-CSF/GM-CSF) (IC025=2.58), which further confirmed that G-CSF or GM-CSF could not increase the reversal rate from infection in patients with sepsis when co-administered with ADCs.